These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 29344438)

  • 1. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome.
    Saleem F; Rizvi SW
    Cureus; 2017 Nov; 9(11):e1844. PubMed ID: 29344438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes.
    Ortiz-Flores AE; Luque-Ramírez M; Escobar-Morreale HF
    Expert Opin Pharmacother; 2018 Dec; 19(17):1915-1926. PubMed ID: 30289728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.
    Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T
    Ther Adv Endocrinol Metab; 2020; 11():2042018820938305. PubMed ID: 32670541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inositol as putative integrative treatment for PCOS.
    Genazzani AD
    Reprod Biomed Online; 2016 Dec; 33(6):770-780. PubMed ID: 27717596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome.
    Banaszewska B; Pawelczyk L; Spaczynski R
    Reprod Biol; 2019 Dec; 19(4):309-315. PubMed ID: 31606349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
    Advani K; Batra M; Tajpuriya S; Gupta R; Saraswat A; Nagar HD; Makwana L; Kshirsagar S; Kaul P; Ghosh AK; Pradhan S; Mehta A; Jaiswal A; Nakhate KT; Kamdi S
    J Obstet Gynaecol; 2020 Jan; 40(1):96-101. PubMed ID: 31339394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
    Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
    Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review.
    Davinelli S; Nicolosi D; Di Cesare C; Scapagnini G; Di Marco R
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of obesity in the development of polycystic ovary syndrome.
    Motta AB
    Curr Pharm Des; 2012; 18(17):2482-91. PubMed ID: 22376149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
    Spritzer PM
    Arq Bras Endocrinol Metabol; 2014 Mar; 58(2):182-7. PubMed ID: 24830595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relevance of inositols treatment for PCOS before and during ART.
    Artini PG; Malacarne E; Tomatis V; Genazzani AD
    Eur Rev Med Pharmacol Sci; 2021 Jul; 25(14):4799-4809. PubMed ID: 34337729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G; Unfer V; Harrath AH; Bizzarri M
    Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
    Balen AH; Morley LC; Misso M; Franks S; Legro RS; Wijeyaratne CN; Stener-Victorin E; Fauser BC; Norman RJ; Teede H
    Hum Reprod Update; 2016 Nov; 22(6):687-708. PubMed ID: 27511809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.
    Sortino MA; Salomone S; Carruba MO; Drago F
    Front Pharmacol; 2017; 8():341. PubMed ID: 28642705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.